Short answer
Arcus Biosciences, Inc. (RCUS) filed its Q1 2026 10-Q quarterly report on May 5, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $7M (down 12.5% year over year) with net income of −$128M.
Q1 2026 key financials · XBRL
- Revenue
- $7M
- −12.5% YoY
- Net income
- −$128M
- −14.3% YoY
- Operating margin
- -1914.3%
- EPS (diluted)
- −$1.02
- +10.5% YoY
Source: XBRL data from the Arcus Biosciences, Inc. (RCUS) Q1 2026 10-Q on SEC EDGAR. USD.
Arcus Biosciences, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No newly added risk factor identified; section is truncated and does not state changes from the 2025 10-K
- Clinical failure risk heightened by STAR-221 discontinuation after December 2025 interim analysis showed no benefit versus standard of care
- Regulatory approval risk from authorities requiring additional studies for intra-portfolio combination therapies
- Near-term development risk from delays in late-stage clinical trials, including enrollment, safety events, manufacturing, and CRO performance
- Liquidity risk with $876 million cash, equivalents, and marketable securities funding operations until at least the second half of 2028
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Arcus Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.